|
Spexis AG
/ Key word(s): Half Year Results
Allschwil, Switzerland, August 31, 2022 Spexis announces presentation of half-year 2022 financial results and participation at upcoming industry and investor events in September Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a live call and webcast to discuss its half-year 2022 financial results and provide a business update on September 6, 2022, 8am ET / 2pm CET. To participate, please use the following numbers: France: +33 (0)1 70 730 3 39 Germany: +49 (0)69 22222 5197 Italy: Switzerland: +41 (0)44 580 7279 United Kingdom +44 (0)330 165 4012 United States Please dial in approximately 10 minutes prior to the start of the call. When asked, please provide the name of the event – “Spexis H1 2022 Financial Results and Business Update” – and the following confirmation code: 7688870. The presentation will also be available via webcast:
A replay of the call will be available on the Company’s website in the Investor Relations – Calendar section or via the above link. In addition, management will participate at the following events in September:
Stephan Wehselau, COO, will give a company presentation on September 6th at 10:45 AM CET and will also meet with investors.
Dr. Wager will give a company presentation and meet with investors. September 28-29, 2022, Boston, U.S. (in-person) & October 4-5, 2022 (virtual) Dr. Wager will participate in this partnering event. Anyone interested in speaking with the company is invited to request a meeting via the platform. For further information please contact:
About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. For further information, please visit: . Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
End of Media Release |
| Language: | English |
| Company: | Spexis AG |
| Hegenheimermattweg 125 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | |
| Fax: | |
| E-mail: | |
| Internet: | |
| ISIN: | CH0106213793 |
| Valor: | SPEX |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1431709 |
| End of News | EQS News Service |
|
|
1431709 31.08.2022 CET/CEST
